sur MAUNA KEA TECHNOLOGIES (EPA:MKEA)
Mauna Kea Technologies Achieves Milestone with CLIMB Study
Mauna Kea Technologies has announced a significant achievement for its Cellvizio technology. The CLIMB study will be featured in the ASGE Presidential Plenary Session at Digestive Disease Week 2026. This session is known for spotlighting impactful endoscopy research.
The CLIMB study, led by Dr. Somashekar Krishna, involved over 500 patients and demonstrated the superior diagnostic capabilities of EUS-nCLE. This method showed higher accuracy in diagnosing pancreatic cystic lesions compared to standard methods.
Cellvizio's selection indicates its growing clinical importance in managing pancreatic cysts. The study also covered real-time diagnosis, artificial intelligence applications, and medico-economic analyses favoring less invasive procedures.
Sacha Loiseau, CEO, emphasized the study's recognition of Cellvizio's accuracy and its potential to influence clinical practices further.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de MAUNA KEA TECHNOLOGIES